A NEW medication for type 2 diabetes may also help tackle non-alcoholic fatty liver disease, a condition linked to type 2 and obesity. It is caused by a build-up of fat in the liver, leading to inflammation, scarring, and potentially liver failure.
A study presented at the recent Endocrine Society meeting in Chicago, found that the diabetes drug empagliflozin, given daily for 20 weeks along with standard diabetes drugs, reduced patients’ liver fat on average from 16 to 11 per cent (with no change for patients on standard drugs). The findings are the first to show this effect on liver fat in humans.
© Solo dmg media
